AbbVie Bid for Biotech Could Expand with Experimental Drug
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Curious about your investment portfolio? Discover what to include to ensure a balanced and profitable mix of assets.
23,656 articlesAbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Coca-Cola shares edge higher as a refreshed coca cola price prediction points to roughly 12% upside. Strong Q1 result...
YieldMax's MSTY ETF continues to pay weekly distributions while its NAV slides, signaling rising risk for investors. ...
Investors fear there is no clean exit from the Iran conflict, leaving Wall Street bracing for volatility as options f...
A 70-year-old inherits $100,000 with almost nothing saved and converts it into guaranteed lifetime income with a sing...
A high-net-worth parent in his 40s faces a tough choice: retire early or stay employed to support his kids’ future. M...
As geopolitical risk stays elevated, investors are reevaluating defense allocations. Lessons from WWII’s most feared ...
GSK has seen a steep run in its stock, prompting questions about whether the rally still offers upside. This article ...
Oil holds above $90, giving EWZ a turbocharged push as Petrobras and Vale ride commodity tailwinds. The Brazil-focuse...
A new ETF aims to monetize the price swings of Rocket Lab and other space names by selling weekly put spreads to fund...
Lumentum’s March 23 S&P 500 inclusion has sparked renewed buying and a broader market debate about how far the rally ...
Nine months after Jim Cramer touted Energy Transfer as a top dividend pick for retirees, the stock has delivered on i...